Q2 delivered strong profitability and 10.9% revenue growth, driven by Rx segment expansion and the launch of apotea.no in Norway. Adjusted EBIT margin reached 5.2%, with continued focus on growth initiatives and operational efficiency.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.